
Jan 20 (Reuters) - Corvus Pharmaceuticals Inc CRVS.O:
CORVUS PHARMACEUTICALS ANNOUNCES POSITIVE DATA FROM COHORT 4 CONFIRMING RESULTS FOR PLACEBO-CONTROLLED PHASE 1 CLINICAL TRIAL OF SOQUELITINIB FOR ATOPIC DERMATITIS
CORVUS PHARMACEUTICALS INC - 75% ACHIEVED EASI 75, 25% EASI 90, 33% IGA 0/1
CORVUS PHARMACEUTICALS INC - PLANS PHASE 2 TRIAL FOR SOQUELITINIB IN Q1 2026
CORVUS PHARMACEUTICALS : COHORT 4 DATA DEMONSTRATED POSITIVE SAFETY AND EFFICACY RESULTS